Can prior vaccinations against certain infections confer protection against developing melanoma?

Medical Journal of Australia

Volumn 191, Issue 9, 2009, Pages 478-479

  Grange, John M ^a   Krone, Bernd ^b,c   Kölmel, Klaus F ^b   Mastrangelo, Giuseppe ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Laboratory Medicine Institute Kassel   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; VACCINIA VACCINE; YELLOW FEVER VACCINE; SMALLPOX VACCINE;

CANCER PREVENTION; CANCER RISK; CD8+ T LYMPHOCYTE; EDITORIAL; HUMAN; INCIDENCE; MELANOMA; PROGNOSIS; RISK REDUCTION; ENDOGENOUS RETROVIRUS; IMMUNOLOGY;

BCG VACCINE; ENDOGENOUS RETROVIRUSES; HUMANS; MELANOMA; SMALLPOX VACCINE; YELLOW FEVER VACCINE;

EID: 73349127490     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2009.tb02907.x     Document Type: Editorial

References (10)

1. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009; 27: 3-9.
2. Australian Institute of Health and Welfare and Australian Association of Cancer Registries. Cancer in Australia: an overview, 2006. Cancer Series no. 37. Canberra: AIHW, 2007. (AIHW Cat. No. CAN 32.) http://www.aihw.gov.au/ publications/index.cfm/title/10476 (accessed Sep 2009).
3. Maurer S, Kölmel K. Spontaneous regression of melanoma. Monograph no. 19. New York: Cancer Research Institute, 1997.
4. Krone B, Kölmel KF, Grange JM, et al. Impact of vaccinations and infectious diseases on melanoma risk - evaluation of an EORTC case-control study. Eur J Cancer 2003; 39: 2372-2378. (Pubitemid 37214862)
5. Kölmel KF, Grange JM, Krone B, et al. Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur J Cancer 2005; 41: 118-125. (Pubitemid 40029664)
6. Schiavetti F, Thonnard J, Colau D, et al. A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res 2002; 62: 5510-5516.
7. Serafino A, Balestrieri E, Pierimarchi P, et al. The activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation. Exp Cell Res 2009; 315: 849-862.
8. Krone B, Kölmel KF, Henz BM, Grange JM. Protection against melanoma by vaccination with bacille Calmette-Guérin (BCG) and/or vaccinia: an epidemiology-based hypothesis on the nature of a melanoma risk factor and its immunological control. Eur J Cancer 2005; 41: 104-117. (Pubitemid 40029663)
9. Mastrangelo G, Krone B, Fadda E, et al. Does yellow fever 17D vaccine protect against melanoma? Vaccine 2009; 27: 588-591.
10. Grange JM, Krone B, Stranford JL. Immunotherapy for malignant melanoma - tracing Ariadne's thread through the labyrinth. Eur J Cancer 2009; 45: 2266-2273.